Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

DelveInsight’s, “Gastric Cancer Pipeline Insight” report provides comprehensive insights about 200+ companies and 220+ ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

Immune checkpoint inhibitors (ICPis) have revolutionized the therapeutic landscape of lung cancer with unprecedented survival results in most of the ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

The global opioid analgesics market is poised for substantial growth, projected to expand from USD 43.3 billion in 2023 to USD 72.0 billion by 2033, at a robust Compound Annual Growth Rate (CAGR) of 5 ...